Literature DB >> 11789403

Stereotactic radiotherapy of targets in the lung and liver.

J Wulf1, U Hädinger, U Oppitz, W Thiele, R Ness-Dourdoumas, M Flentje.   

Abstract

BACKGROUND: Stereotactic irradiation of extracranial targets offers a non-invasive treatment modality for patients with localized tumors, which are not amenable for surgery or other invasive approaches because of age or impaired medical condition. The purpose of the study was the evaluation of the method to achieve local control of irradiated targets in relation to treatment toxicity. PATIENTS AND METHODS: Irradiation was performed as hypofractionated treatment in three fractions of 10 Gy each, normalized to the PTV enclosing 65% isodose with patient fixation in a stereotactic body frame. The isocenter was localized by stereotactic coordinates. Targets were circumscribed tumors in the lung (n = 27) and liver (n = 24) not amenable for other treatment modalities: primary lung cancer (n = 12), local recurrences of lung cancer (n = 4), lung metastases (n = 11), liver metastases (n = 23) and one cholangiocellular carcinoma. Median CTV/PTV for targets in the lung was 57/113 cm3 (min/max 5-277 cm3/17-343 cm3) and for targets in the liver 50/102 cm3 (min/max 9-516 cm3/42-772 cm3). Median follow-up for targets in the lung was 8 months (2-33) and 9 months (2-28) for liver targets. Local control was defined as complete or partial remission and stable disease, measured by repeated CT scans after 6 weeks and in 3 months intervals. Treatment toxicity was evaluated according to the WHO score.
RESULTS: Crude local control was 85% for pulmonary targets and 83% for hepatic targets. Actuarial local control after 1 and 2 years was 76% and 76% for lung tumors and 76% and 61% for liver tumors. Actuarial overall patient survival was 48% after 1 year and 21% after 2 years for targets in the lung and 71% and 43% for targets in the liver. No acute grade 3-5 side effects were observed. Serious late toxicity occurred in two patients: a chronic ulceration of the esophagus at a target close to the mediastinum after 3 months (grade 3) and fatal bleeding from the pulmonary artery after 9 months (grade 5) in a previously irradiated patient. It remained unclear, whether the bleeding was a side effect of irradiation or due to tumor infiltration.
CONCLUSION: Hypofractionated stereotactic irradiation of targets in the lung and liver is a locally effective treatment with actuarial local control rates of 76% after 1 year and 61-76% after 2 years without relevant acute toxicity. Severe late toxicity did not occur, if targets close to the mediastinum were avoided.

Entities:  

Mesh:

Year:  2001        PMID: 11789403     DOI: 10.1007/pl00002379

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  48 in total

1.  A novel technique to enable experimental validation of deformable dose accumulation.

Authors:  Carolyn J Niu; Warren D Foltz; Michael Velec; Joanne L Moseley; Adil Al-Mayah; Kristy K Brock
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

Review 2.  [Radiotherapy of hepatic metastases].

Authors:  S E Combs; K K Herfarth; D Habermehl; J Debus
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

Review 3.  Review and uses of stereotactic body radiation therapy for oligometastases.

Authors:  Filippo Alongi; Stefano Arcangeli; Andrea Riccardo Filippi; Umberto Ricardi; Marta Scorsetti
Journal:  Oncologist       Date:  2012-06-20

4.  A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?

Authors:  Carsten Nieder; Nicolaus H Andratschke; Matthias Guckenberger
Journal:  Ann Transl Med       Date:  2015-07

5.  [Stereotactic radiation therapy for liver metastases].

Authors:  K K Herfarth; J Debus
Journal:  Chirurg       Date:  2005-06       Impact factor: 0.955

6.  A method for improved verification of entire IMRT plans by film dosimetry.

Authors:  Vesna Jacob; Peter Kneschaurek
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

Review 7.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

8.  Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events.

Authors:  T Inoue; R-J Oh; H Shiomi; N Masai; H Miura
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

9.  Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases.

Authors:  Max Seidensticker; Peter Wust; Ricarda Rühl; Konrad Mohnike; Maciej Pech; Gero Wieners; Günther Gademann; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-03-24       Impact factor: 3.481

10.  Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.

Authors:  Jung Hyun Kwon; Si Hyun Bae; Ji Yoon Kim; Byung Ock Choi; Hong Seok Jang; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Kyu Won Chung
Journal:  BMC Cancer       Date:  2010-09-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.